|

Neoadjuvant therapy Clinical Trials

6 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Also known as: Neoadjuvant chemotherapy combined with Serplulimab

Pipeline

Phase 2: 3Phase 3: 2

Top Sponsors

  • Sun Yat-sen University2
  • Sichuan Cancer Hospital and Research Institute1
  • Rutgers, The State University of New Jersey1
  • Qilu Hospital of Shandong University1
  • Jiuda Zhao1

Indications

Other5 trials

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
Phase 2
Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer
N/A
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
Phase 3
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Phase 3
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
Phase 2

New Brunswick, New Jersey1 trial

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

Rutgers Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.